Dr. Lisa Anne Tolnitch, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 4101 Macon Pond Rd, Raleigh, NC 27607 Phone: 919-782-8200 |
Dr. Cynthia Lyn Diehl, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 10208 Cerny St, Suite 204, Raleigh, NC 27617 Phone: 919-381-5540 Fax: 919-381-5547 |
Dr. Richard Allen Chiulli, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 2800 Blue Ridge Rd, Ste 503, Raleigh, NC 27607 Phone: 919-782-8210 Fax: 919-781-4650 |
Amirreza Tabatabai Motameni, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 3024 New Bern Ave, Raleigh, NC 27610 Phone: 919-350-7331 |
News Archive
Arena Pharmaceuticals, Inc. and Eisai Inc. reported today that top-line results from the one-year lorcaserin BLOOM-DM trial demonstrate statistically significant weight loss in obese and overweight patients with type 2 diabetes. In this trial, lorcaserin met all three co-primary efficacy endpoints. In addition, as described below, lorcaserin patients taking lorcaserin 10 mg twice daily (BID) achieved statistically significant improvements in multiple secondary endpoints, including HbA1c, as compared to patients randomized to placebo.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that RHB-204 has been granted Fast Track designation by the U.S. Food and Drug Administration for its development as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) - a rare disease for which there is no FDA-approved first-line therapy.
Myconostica Ltd, the UK-based medical diagnostic company developing and commercialising rapid and highly specific tests for life-threatening fungal infections, today presented positive data from a multi-centre prospective evaluation of MycAssay Pneumocystis, the Company's CE marked diagnostic product for detection of Pneumocystis DNA in respiratory samples.
Signum Biosciences, Inc has been awarded a $1.6 million Small Business Innovation Research (SBIR) Phase II grant by the National Institute of Allergy and Infection Diseases (NIAID) to continue the development of its topical STM (Signal Transduction Modulator) anti-inflammatory technology for the treatment of inflammatory skin disease.
Banning smoking in the workplace and increasing taxes on cigarettes have discouraged teens and young adults from taking up smoking, according to a study by researchers at UC San Francisco and UC Merced.
› Verified 3 days ago